AADi Bioscience is a clinical stage biopharmaceutical company developing the a potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Bolt Biotherapeutics is developing its novel Boltbody™ platform for cancer immunotherapy therapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).
Bonraybio is a development-stage medical device company based in Taiwan with an initial focus targeting the infertility market.
Fortis Therapeutics is an immuno-oncology biotechnology company developing novel antibody drug conjugate (ADC) therapies for prostate cancer and multiple myeloma.
HCMedi is an innovative handheld medical device company specializing in inhaled drug delivery systems for respiratory disease control.
Homology Medicines (NASDAQ: FIXX) is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
ReadCoor is a company developing and commercializing fluorescent in situ sequencing (FISSEQ) technology, a new generation sequencing platform enabling high throughput RNA-Seq while preserving sample morphology and providing cellular location and spatial image data.
Privately held companies at the time of Vivo’s initial investment.